Telix Pharmaceuticals Limited Sponsored ADR TLX 深 滬
等待開盤 01-28 09:30:00 美东时间
8.36
+0.710
+9.28%
華盛通- 最 高8.36
- 今 開8.10
- 成交量 22.32万股
- 最 低 8.10
- 昨 收 7.65
- 總市值 28.01亿
- 52周最高 30.36
- 市盈率 靜 87.63
- 換手率 0.07%
- 52周最低 7.1623
- 委 比 -69.02%
- 總股本 3.35亿
- 歷史最高 30.36
- 量 比 1.32
- 振 幅 3.40%
- 歷史最低 7.1623
- 每 手 1
- 風險率 3.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Telix Pharmaceuticals Doses First Participant In U.S. For Its BiPASS Study To Evaluate Use Of Commercial PSMA-PET1 Imaging Agents Illuccix, Gozellix For Initial Prostate Cancer Diagnosis Setting
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a
01-17 03:22
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.
2025-12-22 20:12
Telix Pharma Collaborates With Varian To Develop Clinical Applications That Combine Telix's Theranostic Products And External Beam Radiation Therapy
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel
2025-12-10 20:04
Telix Pharma's ZIRCON-X Study Shows TLX250-CDx Imaging Could Alter Clinical Management In Nearly Half of Patients
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab)
2025-11-20 03:03
Telix Pharmaceuticals to Release Shares from Voluntary Escrow
An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Teli...
2025-10-29 06:18
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
Melbourne, Australia and Indianapolis – Telix Pharmaceuticals announced that updated guidelines from leading nuclear medicine societies now include its investigational PET agent, TLX250-CDx, for imaging renal masses. The expert panel highlighted TLX250-CDx as a non-invasive, accurate method for diagnosing clear cell renal cell carcinoma (ccRCC), referencing data from the successful Phase 3 ZIRCON trial. The inclusion marks a significant step towa...
2025-10-23 11:00
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
Telix Pharmaceuticals has initiated a Phase 1 clinical trial for TLX090, a radiopharmaceutical targeting bone metastases-related pain. Designed to deliver targeted radiation, TLX090 aims to minimize damage to healthy tissues while providing long-lasting pain relief. The SOLACE trial, enroll up to 33 patients, evaluates safety, efficacy, and pharmacokinetics. Existing treatments like opioids and EBRT have significant limitations, making TLX090's n...
2025-10-22 20:00
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820 million amid strong PSMA imaging and reimbursement gains.
2025-10-15 02:11
Telix Pharmaceuticals boosts FY25 guidance after strong Q3
Telix Pharmaceuticals (OTCPK:TLPPF) reported Q3 2025 revenue of $206M, up 53% year-over-year. FY 2025 revenue guidance raised to $800–$820 million, up from prior forecasts. R&D spending to rise 20–25%...
2025-10-14 15:51
